EP1503755A1 — Zonisamide use in obesity and eating disorders
Assigned to Eisai Co Ltd · Expires 2005-02-09 · 21y expired
What this patent protects
The present invention is directed to a method of treating overweight and/or obesity and eating disorders such as binge-eating disorders, bulimia nervosa andanorexia nervosa. The method comprises administering to a subject a pharmaceutical composition comprising an effective amoun…
USPTO Abstract
The present invention is directed to a method of treating overweight and/or obesity and eating disorders such as binge-eating disorders, bulimia nervosa andanorexia nervosa. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of zonisamide(1,2-benzisoxazole-3-methanesulfonamide). The present method provides a sustained and significant weight loss in an overweight subject. The method can be used in conjunction with other therapeutic agents/methods commonly used to treat overweight and eating disorders thus enhancing the therapeutic effect of reducing weight and regulating eating disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.